

# PRESS RELEASE

Lund, SWEDEN – May 23, 2011



---

---

## HANSA MEDICAL ESTABLISH AGREEMENT ON SUBSCRIPTION COMMITMENT AND ISSUING GUARANTEE

On 12 May 2011, Hansa Medical's annual meeting of shareholders resolved to execute a new share issue of MSEK 29 with preferential rights to Hansa Medical's shareholders. Hansa Medical's largest owner, Bo Håkansson, through company, has committed, on the basis of a subscription commitment, to subscribe to his portion of the new share issue, equivalent to approximately 42 percent of the entire issue. Hansa Medical has also entered into an agreement with Bo Håkansson through company for an issuing guarantee for that portion of the new share issue not covered by the subscription commitment, approximately 58 percent. As a result, the new share issue is now fully covered by subscription commitment and issuing guarantee.

**For further information, please contact:**

Emanuel Björne, CEO Hansa Medical AB

Mobile: +46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

### ABOUT HANSA MEDICAL

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.

Hansa Medical AB  
P.O. Box 785  
SE-220 07 Lund, SWEDEN  
Phone +46 46 16 56 70  
Fax +46 46 12 77 75  
[info@hansamedical.com](mailto:info@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

VISITING ADDRESS:  
Scheelevägen 22  
Lund, SWEDEN